Table 5.

Comparisons of clinical data between stages 1–3 cases without TDP-43 and stage 4 cases with TDP-43 at examination closest to onset

	Insula		Ventral striatum		Basal forebrain
	Yes (N=33)	No (N=94)	Yes (N=32)	No (N=94)	Yes (N=23)	No (N=94)
MMSE	23 (11, 29)	25 (7, 30)	23 (11, 29)	25 (7, 30)	23 (17, 29)	25 (7, 30)
Total UPDRS	2 (0, 10)	1 (0, 28)	2 (0, 10)	1 (0, 28)	2 (0, 10)	1 (0, 28)
Boston Naming Test	42 (10, 59)	46 (2, 59)	37 (10, 52)**	46 (2, 59)	36 (10, 58)**	46 (2, 59)
WAIS-Block Design	11 (0, 35)	14 (0, 36)	10 (0, 29)	14 (0, 36)	10 (2, 20)*	14 (0, 36)
COWAT total raw	24 (9, 54)	28 (5, 66)	21 (9, 48)*	28 (5, 66)	21 (9, 33)**	28 (5, 66)
AVLT Delayed Recall	0 (0, 6)	1 (0, 9)	0 (0, 4)*	1 (0, 9)	0 (0, 2)**	1 (0, 9)
NPI-Q Total Severity	3 (0, 14)	2 (0, 11)	2 (0, 14)	2 (0, 11)	2 (1, 14)	2 (0, 11)

MMSE = Mini-Mental State Examination; UPDRS = Unified Parkinson’s Disease Rating Scale; WAIS = Wechsler Adult Intelligence Scale; COWAT = Control Oral Word Association Test; AVLT = Auditory Verbal Learning Test; NPI-Q = brief questionnaire version of the Neuropsychiatric Inventory.

Data shown as median (range). P-values are from Wilcoxon Rank Sum test.

^*p < 0.05,

^**p < 0.01,

^****p < 0.001.